Hematological Agents : Hematopoietic Agents
IVIDA1 “Vidaza injection” 100 mg/vial
適應症：骨髓增生不良症候群高危險性病患：頑固性貧血併有過量芽細胞（RA with excess blasts, RAEB）、轉變中的頑固性貧血併有過量芽細胞（RAEB in transformation, RAEB-T）、及慢性骨髓單核細胞性白血病（chronic myelomonocytic leukemia, CMMoL）。
Usual dose:
Adult (≧12 yrs): SC or IV 75 mg/m(2) SC or IV daily for 7 days; repeat cycle every 4 weeks for as long as patient benefits (minimum 4 to 6 cycles); may increase dose to 100 mg/m(2) if no improvement seen after 2 cycles and the only toxicity is nausea and vomiting; partial response may require additional cycles.
Dose adjustment:
If nadir ANC is between 0.5 and 1.5 x 10(9)/L and platelets are between 25 and 50 x 10(9)/L, give 67% of dose in next course; if nadir ANC is less than 0.5 x 10(9)/L and platelets are less than 25 x 10(9)/L, give 50% of dose in next course, bicarbonate level, unexplained decrease to less than 20 mEq/L: decrease dose by 50% on the next course, renal toxicity, unexplained elevation of BUN or serum creatinine: delay next cycle until values return to normal or baseline and decrease dose by 50% on the next course
Adverse effect:
Chest pain, erythema, erythema at injection site, induration of skin, injection site bruising, injection site pain, injection site reaction, petechiae, pruritic rash, pruritus, constipation, diarrhea, loss of appetite, nausea, vomiting, anemia, ecchymosis, leukopenia any grade, neutropenia any grade, thrombocytopenia any grade, arthralgia, dizziness, headache, insomnia, lethargy, dyspnea, nasopharyngitis, pneumonia, upper respiratory infection, fatigue, fever.